Neurofibromatosis 2

Search with Google Search with Bing
Information
Disease name
Neurofibromatosis 2
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04283669 Active, not recruiting Phase 2 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas February 18, 2020 December 31, 2025
NCT00030043 Completed Phase 1 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors September 2001 August 2003
NCT00863122 Completed Early Phase 1 Concentration and Activity of Lapatinib in Vestibular Schwannomas June 2009 August 2014
NCT00004437 Completed Phase 2 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 October 1999 October 2000
NCT00973739 Completed Phase 2 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors September 2009 November 2012
NCT01490476 Completed Phase 2 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients January 2012 January 2017
NCT02298270 Completed N/A Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype March 2014 July 2015
NCT02811718 Completed N/A Resiliency Training for Patients With NF2 Via Videoconferencing With Skype July 2016 July 2018
NCT02831257 Completed Phase 2 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas August 31, 2016 October 1, 2020
NCT03617276 Completed Reliability of Functional Outcome Measures in Neurofibromatosis 2 September 7, 2016 May 17, 2017
NCT04890132 Enrolling by invitation N/A Vestibular Precision: Physiology & Pathophysiology July 1, 2020 June 30, 2025
NCT01885767 Recruiting Neurofibromatosis (NF) Registry Portal June 2012 June 2050
NCT03079999 Recruiting Phase 2 Study of Aspirin in Patients With Vestibular Schwannoma June 11, 2018 February 2029
NCT05685836 Recruiting 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients October 20, 2022 December 31, 2024
NCT03095248 Suspended Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors May 8, 2017 June 2025
NCT00911248 Terminated Phase 2 PTC299 for Treatment of Neurofibromatosis Type 2 July 31, 2009 March 31, 2012
NCT00004483 Unknown status NF2 Natural History Consortium January 2002
NCT03406208 Unknown status N/A Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing October 1, 2017 January 30, 2022
NCT03893643 Unknown status Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 January 1, 2019 December 31, 2022
MeSH unique ID (MeSH (Medical Subject Headings))
D016518